通过阻断RAS- PI3Kα相互作用,BBO-10203可以抑制瘤生长而不会引起高血糖
Dhirendra K Simanshu1, Rui Xu2, James P Stice2
1NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA.
概括
在临床前模型中,BBO-10203是一种针对酸3-酶α (PI3Kα) 的新型口服药物,可显著抑制瘤. 这种PI3Kα抑制剂有效地减少瘤生长而不会引起高血糖症.
科学领域:
- 癌症学
- 分子生物学
- 药理学
背景情况:
- 酸3-激酶α (PI3Kα) 是一种关键的信号酶,涉及各种癌症.
- 通过RAS激活PI3Kα在瘤发育和进展中起着至关重要的作用.
- 在多种瘤类型中,PIK3CA,KRAS和HER2放大/过度表达的致癌突变是常见的驱动因素.
研究的目的:
- 在临床前癌症模型中评估口服PI3Kα抑制剂BBO-10203的疗效.
- 研究BBO-10203的作用机制,重点关注其与PI3Kα的RAS结合域的特定结合.
- 评估BBO-10203作为单一治疗和与其他向药物的结合的潜力.
主要方法:
- 在临床前的癌症模型中,BBO-10203是口服的.
- 在具有特定瘤突变或放大的瘤中评估PI3Kα激活的抑制.
- 在各种瘤类型中评估瘤生长抑制,包括具有KEAP1和STK11突变的瘤.
- 组合疗法包括CDK4/ 6,ER,HER2和KRAS- G12C的抑制剂.
主要成果:
- BBO-10203与PI3Kα的RAS结合域结合,防止其被RAS蛋白激活.
- 这种药物在瘤性KRAS,PIK3CA突变或HER2放大/过度表达的瘤中表现出PI3Kα抑制.
- 在多种瘤类型中观察到显著的瘤生长抑制.
- 在组合疗法中,特别是在KEAP1和STK11突变的瘤中,观察到更高的疗效.
结论:
- 在临床前模型中,BBO-10203是一种强大的PI3Kα抑制剂,具有广泛的抗瘤活性.
- 当与其他向治疗,包括CDK4/ 6,ER,HER2和KRAS- G12C抑制剂结合使用时,该药物的疗效会增强.
- 在不引起高血糖的情况下,BBO-10203具有抗瘤作用,这表明其具有明显的治疗窗口.
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
The Ras Gene
6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.2K
The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K


